恩替卡韦

常用名 恩替卡韦 英文名 Entecavir
CAS号 142217-69-4 分子量 277.279
密度 1.8±0.1 g/cm3 沸点 734.2ºC at 760 mmHg
分子式 C12H15N5O3 熔点 249-252ºC
MSDS恩替卡韦的MSDS|SDS|pdf下载 美版 闪点 397.9ºC

 恩替卡韦用途


为鸟嘌呤核苷类似物,对乙肝病毒(HBV)多聚酶具有抑制作用。

 恩替卡韦作用


本品为鸟嘌呤核苷类似物,对乙肝病毒(HBV)多聚酶具有抑制作用。它能够通过磷酸化成为具有活性的三磷酸盐,三磷酸盐在细胞内的半衰期为15小时。通过与HBV多聚酶的天然底物三磷酸脱氧鸟嘌呤核苷竞争,恩替卡韦三磷酸盐能抑制病毒多聚酶(逆转录酶)的所有三种活性:(1)HBV多聚酶的启动;(2)前基因组mRNA逆转录负链的形成;(3)HBV DNA正链的合成。恩替卡韦三磷酸盐对HBV DNA多聚酶的抑制常数(Ki)为0.0012μM。恩替卡韦三磷酸盐对细胞的α、β、δDNA多聚酶和线粒体γDNA多聚酶抑制作用较弱,Ki值为18至于160μM。

 恩替卡韦名称

[ 中文名 ]: 恩替卡韦
[ 英文名 ]: entecavir (anhydrous)
[中文别名 ]: ENTECAVIR(一水合物)
2-氨基-9-((1S,3R,4S)-4-羟基-3-(羟甲基)-2-甲烯基环戊基)-3H-嘌呤-6(9H)-酮
9-(4-羟基-3-羟甲基-2-亚甲基环戊-1-基)鸟嘌呤
[英文别名 ]: 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-1,9-dihydro-6H-purin-6-one
entecavir (anhydrous)
6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
Baraclude
entecavir
9H-purin-6-ol, 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
UNII-NNU2O4609D
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-9H-purin-6-ol

 恩替卡韦物理化学性质

[ 密度 ]: 1.8±0.1 g/cm3
[ 沸点 ]: 734.2ºC at 760 mmHg
[ 熔点 ]: 249-252ºC
[ 分子式 ]: C12H15N5O3
[ 分子量 ]: 277.279
[ 闪点 ]: 397.9ºC
[ 精确质量 ]: 277.117493
[ PSA ]: 130.05000
[ LogP ]: -0.96
[ 外观性状 ]: 白色至灰白色/黄色结晶粉末
[ 折射率 ]: 1.837

 恩替卡韦MSDS

Material Safety Data Sheet

Section1. Identification of the substance
Product Name: Entecavir
Synonyms:

Section2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section3. Composition/information on ingredients.
Ingredient name:Entecavir
CAS number:142217-69-4

Section4. First aid measures
Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution:Wear approved mask/respirator
Hand precaution:Wear suitable gloves/gauntlets
Skin protection:Wear suitable protective clothing
Eye protection:Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section7. Handling and storage
Handling:This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage:Store in closed vessels, refrigerated.

Section8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section9. Physical and chemical properties
Appearance:Not specified
Boiling point:No data
Melting point:No data
Flash point:No data
Density:No data
Molecular formula: C12H15N5O3
Molecular weight: 277.3

Section10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section11. Toxicological information
No data.

Section12. Ecological information
No data.

Section13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section14. Transportation information
Non-harzardous for air and ground transportation.

Section15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

 恩替卡韦安全信息

[ 危险品运输编码 ]: NONH for all modes of transport
[ 海关编码 ]: 2933990090

 恩替卡韦合成线路

~71%

文献:HANMI HOLDINGS CO., LTD. Patent: US2011/251387 A1, 2011 ; Location in patent: Page/Page column 8 ;

~88%

文献:ScinoPharm Taiwan, Ltd. Patent: US2011/201809 A1, 2011 ; Location in patent: Page/Page column 18 ;

~86%

文献:ALPHORA RESEARCH INC.; ALBERICO, Dino; CLAYTON, Joshua; DIXON, Craig; GORIN, Boris Patent: WO2011/150512 A1, 2011 ; Location in patent: Page/Page column 11 ;

~72%

文献:AUSUN PHARMATECH. CO., LTD.; Zheng, Zhiguo Patent: US2013/217879 A1, 2013 ; Location in patent: Paragraph 0356-0357 ;

~81%

文献:AUSUN PHARMATECH. CO., LTD.; Zheng, Zhiguo Patent: US2013/217879 A1, 2013 ; Location in patent: Paragraph 0358 ;

~75%

文献:AUSUN PHARMATECH. CO., LTD.; Zheng, Zhiguo Patent: US2013/217879 A1, 2013 ; Location in patent: Paragraph 0359 ;

~49%

文献:ALPHORA RESEARCH INC.; ALBERICO, Dino; CLAYTON, Joshua; DIXON, Craig; GORIN, Boris Patent: WO2011/150512 A1, 2011 ; Location in patent: Page/Page column 9-10 ;

~71%

文献:AUSUN PHARMATECH. CO., LTD.; Zheng, Zhiguo Patent: US2013/217879 A1, 2013 ; Location in patent: Paragraph 0351-0352 ;

~55%

文献:AUSUN PHARMATECH. CO., LTD.; Zheng, Zhiguo Patent: US2013/217879 A1, 2013 ; Location in patent: Paragraph 0353-0355 ;

~%

文献:ESTEVE QUÍMICA, S.A.; BERENGUER MAIMÓ, Ramón; BADIA PÉREZ, Laura; GASANZ GUILLÉN, Yolanda; VELASCO TURBAU, Javier; ARIZA PIQUER, Javier Patent: WO2013/76236 A1, 2013 ; Location in patent: Page/Page column 25 ;

~82%

文献:ScinoPharm Taiwan, Ltd. Patent: US2011/201809 A1, 2011 ; Location in patent: Page/Page column 18 ;

~84%

文献:ScinoPharm Taiwan, Ltd. Patent: US2011/201809 A1, 2011 ; Location in patent: Page/Page column 17 ;

~88%

文献:Bisacchi; Chao; Bachard; Daris; Innaimo; Jacobs; Kocy; Lapointe; Martel; Merchant; Slusarchyk; Sundeen; Young; Colonno; Zahler Bioorganic and Medicinal Chemistry Letters, 1997 , vol. 7, # 2 p. 127 - 132

~44%

文献:Zhou, Maotang X.; Reiff, Emily A.; Vemishetti, Purushotham; Pendri, Yadagiri R.; Singh, Ambarish K.; Prasad, Siva Josyula; Dhokte, Ulhas P.; Qian, Xinhua; Mountford, Pia; Hartung, Kerry B.; Sailes, Helen Patent: US2005/272932 A1, 2005 ; Location in patent: Page/Page column 19-20 ;

~96%

文献:Zhou, Bing; Li, Yuanchao Tetrahedron Letters, 2012 , vol. 53, # 5 p. 502 - 504

~87%

文献:Liu, Xiaoyu; Jiao, Xiaozhen; Wu, Qian; Tian, Chengsen; Li, Renze; Xie, Ping Tetrahedron Letters, 2012 , vol. 53, # 29 p. 3805 - 3807

~%

文献:Tetrahedron Letters, , vol. 53, # 5 p. 502 - 504

~%

文献:US2011/251387 A1, ;

~%

文献:EP2594569 A1, ;

~%

文献:EP2594569 A1, ;

~%

文献:EP2594569 A1, ;

~%

文献:EP2594569 A1, ;

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:WO2013/76236 A1, ;

~%

文献:Bioorganic and Medicinal Chemistry Letters, , vol. 7, # 2 p. 127 - 132

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:WO2013/76236 A1, ;

~%

文献:EP2594569 A1, ; US2013/217879 A1, ;

~%

文献:US2013/217879 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:US2011/251387 A1, ;

~%

文献:Tetrahedron Letters, , vol. 53, # 5 p. 502 - 504

~%

文献:Journal of Organic Chemistry, , vol. 78, # 11 p. 5482 - 5491

~%

文献:Journal of Organic Chemistry, , vol. 78, # 11 p. 5482 - 5491

~%

文献:US2013/217879 A1, ;

~%

文献:WO2011/150512 A1, ;

 恩替卡韦上下游产品

恩替卡韦上游产品  4

恩替卡韦下游产品  0

 恩替卡韦海关

[ 海关编码 ]: 2933990090
[ 中文概述 ]: 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
[申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期
[ Summary ]: 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 恩替卡韦文献18

更多文献
Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.

Biochem. Biophys. Res. Commun. 452(3) , 315-21, (2014)

Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) plays a central role in chronic HBV infection. However, analysis of the molecular mechanism of cccDNA formation is difficult because of ...

Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes.

J. Med. Virol. 87(4) , 601-8, (2015)

Mutations in the basal core promoter (BCP) and precore (PC) regions of the hepatitis B virus (HBV) are more common in genotypes B and C than in genotype A, suggesting that these mutations might affect...

Decreased liver distribution of entecavir is related to down-regulation of Oat2/Oct1 and up-regulation of Mrp1/2/3/5 in rat liver fibrosis.

Eur. J. Pharm. Sci. 71 , 73-9, (2015)

We aimed to elucidate whether entecavir was taken-up into liver by transporters and clarify the possible molecular mechanisms of changes in the distribution of entecavir in rat liver fibrosis.Thioacet...